IKT (STOCKS)
Inhibikase Therapeutics, Inc. Common Stock
$1.830000
+0.150000 (+8.93%)
Prev close: $1.680000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Mark T. Iwicki
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $240.96M
- Employees
- 16
- P/E (TTM)
- -4.21
- P/B (TTM)
- 1.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.10 | $-0.11 | +0.0094 | +8.59% |
|
Dec 2025 (Q4)
|
$-0.09 | $-0.10 | +0.0142 | +13.63% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.13 | +0.0013 | +0.99% |
|
Jun 2025 (Q2)
|
$-0.11 | $-0.09 | -0.0191 | -21.01% |
Financial Statements
| Revenues | $3.72M |
| Costs And Expenses | $55.22M |
| Selling, General, and Administrative Expenses | $25.68M |
| Research and Development | $30.12M |
| Operating Income/Loss | -$55.22M |
| Income/Loss From Continuing Operations After Tax | -$2.75M |
| Income/Loss From Continuing Operations Before Tax | -$2.38M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Income/Expense After Provision For Losses | $4.26M |
| Interest Income/Expense Operating, Net | $4.26M |
| Net Income/Loss | -$50.96M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$50.96M |
| Net Income/Loss Available To Common Stockholders, Basic | -$50.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.43 |
| Diluted Earnings Per Share | -$0.43 |
| Basic Average Shares | 360,809,915 |
| Diluted Average Shares | 360,809,915 |
| Assets | $173.33M |
| Current Assets | $172.18M |
| Prepaid Expenses | $514.91K |
| Other Current Assets | $171.66M |
| Noncurrent Assets | $1.16M |
| Non-current Prepaid Expenses | $1.00M |
| Other Non-current Assets | $155.76K |
| Liabilities | $5.71M |
| Current Liabilities | $5.71M |
| Accounts Payable | $1.59M |
| Other Current Liabilities | $4.12M |
| Noncurrent Liabilities | $0.00 |
| Equity | $167.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $167.62M |
| Liabilities And Equity | $173.33M |
| Net Cash Flow From Operating Activities | -$35.74M |
| Net Cash Flow From Operating Activities, Continuing | -$35.74M |
| Net Cash Flow From Investing Activities | -$99.49M |
| Net Cash Flow From Investing Activities, Continuing | -$99.49M |
| Net Cash Flow From Financing Activities | $128.31M |
| Net Cash Flow From Financing Activities, Continuing | $128.31M |
| Net Cash Flow | -$6.92M |
| Net Cash Flow, Continuing | -$6.92M |
| Other Comprehensive Income/Loss | -$50.99M |